Raptor seeks FDA approval for RP103

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) submitted an NDA to FDA for RP103 to treat nephropathic cystinosis. Raptor requested Priority Review for the application. On Monday, Raptor said EMA accepted ...